F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study. This study initiates the IV Phase I clinical development of F901318 with the oral programme expected to commence in the near future.

F901318 is being developed by F2G to treat invasive aspergillosis and other life-threatening fungal infections and is of a novel class of antifungals acting against a new cellular target. The discovery and development of F901318 represents a major advance in the treatment of serious fungal disease as currently there are very limited treatment options and resistance to existing drugs is becoming a serious problem. F901318 is highly active against all known azole-resistant aspergilli.

Dr Tony Kennedy, F2G’s Chief Scientific Officer said:

We are delighted to commence our clinical development of F901318 based on encouraging preclinical safety and efficacy studies and I look forward to rapidly progressing both our oral and IV programmes.

Ian Nicholson, F2G’s CEO commented:

F901318 is a significant addition to the antifungal armamentarium as there have not been any new classes of antifungal agents s approved for many years and growing resistance presents a considerable challenge in this seriously ill patient population. We believe that F901318 represents a truly innovative approach in this area and we are dedicated to providing improved treatment options for patients with life threatening aspergillus infections.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Advanced tools for Glycobiology research